Survival Estimation | List of Frontiers open access articles

Original Research

Published on 14 Jul 2023

Nomogram incorporating potent inflammatory indicators for overall survival estimation of patients with primary oral squamous cell carcinoma

in Molecular and Cellular Oncology

Hai-xuan Wu
Shi Cheng
Fan Liu
Jun-jie Lin
Su-na Huang
Cheng-li Wang
Bin Zhou
Zhong-qi Liu
Ming-hui Cao

Frontiers in Oncology

doi 10.3389/fonc.2023.1197049

2,975 views
4 citations

Methods

Published on 09 Mar 2023

Detection of missed deaths in cancer registry data to reduce bias in long-term survival estimation

in Cancer Epidemiology and Prevention

Stefan Dahm
Benjamin Barnes
Klaus Kraywinkel

Frontiers in Oncology

doi 10.3389/fonc.2023.1088657

2,067 views
3 citations

Original Research

Published on 30 Jun 2022

Incremental Value of Radiomics in 5-Year Overall Survival Prediction for Stage II–III Rectal Cancer

in Radiation Oncology

Ke Nie
Peng Hu
Jianjun Zheng
Yang Zhang
Pengfei Yang
Salma K. Jabbour
Ning Yue
Xue Dong
Shufeng Xu
Bo Shen

Frontiers in Oncology

doi 10.3389/fonc.2022.779030

3,991 views
11 citations

Original Research

Published on 17 Nov 2022

Novel T-cell signature based on cell pair algorithm predicts survival and immunotherapy response for patients with bladder urothelial carcinoma

in Cancer Immunity and Immunotherapy

Xin Yan
Xiao Zhang
Hua-Hui Wu
Shao-Jie Wu
Xiao-Yu Tang
Tong-Zu Liu
Sheng Li

Frontiers in Immunology

doi 10.3389/fimmu.2022.994594

3,890 views
5 citations

Original Research

Published on 11 Dec 2025

Adrenomedullin orchestrates treatment resistance in hepatocellular carcinoma via immune microenvironment remodeling

in Cancer Genetics and Oncogenomics

Xixi Gao
Yongliang Sun
Jia Huang
Li Xu
Hanchun Huang
Zhiying Yang

Frontiers in Genetics

doi 10.3389/fgene.2025.1721263

1,612 views

Original Research

Published on 07 Dec 2022

A novel risk classification system based on the eighth edition of TNM frameworks for esophageal adenocarcinoma patients: A deep learning approach

in Gastrointestinal Cancers: Gastric and Esophageal Cancers

Qiang Shen
Hongyu Chen

Frontiers in Oncology

doi 10.3389/fonc.2022.887841

2,033 views
3 citations

Original Research

Published on 24 Sep 2024

Efficacy of Danlou tablets in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a multicenter prospective cohort study

in General Cardiovascular Medicine

Yajie Cai
Qiaoning Yang
Ruixi Xi
Furong Yang
Feng Gu
Yang Zhao
Ming Guo
Guoju Dong
Zhuye Gao
Changgeng Fu

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2024.1420194

2,703 views
1 citation

Systematic Review

Published on 14 May 2024

Progression-free survival estimation of docetaxel-based second-line treatment for advanced non-small cell lung cancer: a pooled analysis from 18 randomized control trials

in Thoracic Oncology

Chaithra N
Anisha Jain
Sahana C
Bhargav Shreevatsa
Saravanan Rajendrasozhan
Chandan Dharmashekar
Kuralayanapalya Puttahonnappa Suresh
Sharanagouda S. Patil
Pranav Singh
Prashant Vishwanath

Frontiers in Oncology

doi 10.3389/fonc.2024.1298786

3,912 views

Articles

Nomogram incorporating potent inflammatory indicators for overall survival estimation of patients with primary oral squamous cell carcinoma

Detection of missed deaths in cancer registry data to reduce bias in long-term survival estimation

Incremental Value of Radiomics in 5-Year Overall Survival Prediction for Stage II–III Rectal Cancer

Novel T-cell signature based on cell pair algorithm predicts survival and immunotherapy response for patients with bladder urothelial carcinoma

Adrenomedullin orchestrates treatment resistance in hepatocellular carcinoma via immune microenvironment remodeling

A novel risk classification system based on the eighth edition of TNM frameworks for esophageal adenocarcinoma patients: A deep learning approach

Efficacy of Danlou tablets in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a multicenter prospective cohort study

Progression-free survival estimation of docetaxel-based second-line treatment for advanced non-small cell lung cancer: a pooled analysis from 18 randomized control trials